Rucaparib

Generic Name: Rucaparib

Brand Names: Rubraca

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₈FN_₃O

CAS Number: 283173-50-2

Unique Ingredient Identifier: 8237F3U7EH

Background: Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...

Indication: Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer

Associated Therapies: Maintenance therapy

Clinical Trials

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: AsiDNA
Drug: Niraparib
Drug: Olaparib
Drug: Rucaparib

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 13

Registration Number: NCT04826198

Locations: 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷
Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷
Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France

and more 3 locations

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Phase 3

Completed

Conditions: Ovarian Cancer
Peritoneal Cancer
Epithelial Ovarian Cancer
Other Solid Tumor
Metastatic Castration-Resistant Prostate Cancer
Fallopian Tube Cancer

Interventions: Drug: Rucaparib

First Posted Date: 2020-12-21

Last Posted Date: 2024-05-07

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 34

Registration Number: NCT04676334

Locations: 🇮🇱
Carmel Medical Center, Haifa, Israel
🇮🇹
Istituto per la Ricerca e la Cura del Cancro Istituto di Candiolo, Candiolo, Torino, Italy
🇨🇦
Institut De Recherche De L'Hospital D'Ottawa, Ottawa, Ontario, Canada

and more 22 locations

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Phase 2

Active, not recruiting

Conditions: Leiomyosarcoma

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2020-11-10

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT04624178

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

and more 4 locations

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

Completed

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
Epithelial Ovarian Cancer

First Posted Date: 2020-09-07

Last Posted Date: 2022-09-23

Lead Sponsor: Grupo Español de Investigación en Cáncer de Ovario

Target Recruit Count: 52

Registration Number: NCT04539327

Locations: 🇪🇸
Hospital Torrecárdenas, Almería, Andalucía, Spain
🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, Comunitat Valenciana, Spain
🇪🇸
Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain

and more 20 locations

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Phase 2

Suspended

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab
Drug: Rucaparib

First Posted Date: 2020-02-19

Last Posted Date: 2024-03-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 130

Registration Number: NCT04276376

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Rucaparib
Drug: Copanlisib

First Posted Date: 2020-02-05

Last Posted Date: 2024-04-05

Lead Sponsor: Brown University

Target Recruit Count: 13

Registration Number: NCT04253262

Locations: 🇺🇸
Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco, California, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients

Phase 3

Completed

Conditions: Clear Cell Carcinoma
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Placebos
Drug: Rucaparib

First Posted Date: 2020-01-13

Last Posted Date: 2024-11-15

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 42

Registration Number: NCT04227522

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪
Städtisches Klinikum Dessau, Dessau, Germany
🇩🇪
Städtisches Krankenhaus Kiel, Kiel, Germany

and more 14 locations

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Phase 1

Active, not recruiting

Conditions: Small Cell Lung Cancer
Extra-Pulmonary Small Cell Carcinomas

Interventions: Drug: PLX038
Drug: Rucaparib
Drug: Ondansetron

First Posted Date: 2019-12-24

Last Posted Date: 2024-01-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT04209595

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Phase 1

Completed

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Rucaparib
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2019-11-27

Last Posted Date: 2023-06-29

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 8

Registration Number: NCT04179396

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸
Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Phase 2

Terminated

Conditions: Solid Tumor

Interventions: Drug: Rucaparib

First Posted Date: 2019-11-21

Last Posted Date: 2023-10-02

Lead Sponsor: pharmaand GmbH

Target Recruit Count: 83

Registration Number: NCT04171700

Locations: 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States

and more 15 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy